Maven Clinic launches integrated women’s health platform with GLP-1 therapy and hormone support
Key takeaways
- Maven Clinic has launched a direct-to-consumer platform in the US that integrates GLP-1 and hormone therapy with a network of women’s health providers across 30 specialties.
- The service aims to replace fragmented health care by treating connected metabolic, hormonal, and reproductive symptoms as a single care experience rather than isolated issues.
- A company report highlighted severe gaps in existing care, revealing that over a third of women receive inadequate follow-up care and nearly half turn to social media for health guidance.

Virtual women’s clinic Maven Clinic has launched its direct-to-consumer platform, which connects GLP-1 and hormonal care to its digital network of women’s health providers in the US. The service provides care across more than 30 fields, including OB-GYN, mental health, nutrition, physical therapy, and lactation consulting.
The company says women’s health services tend to focus on one condition or one moment in time in a fragmented system. As an alternative, the platform aims to connect women’s clinic visits through a single care experience.
“Metabolism affects hormones, hormones affect mental health, and reproductive history affects all of it,” says Kate Ryder, founder and CEO of Maven Clinic.

“Women don’t experience their health in silos. Maven was built to connect the dots. Now any woman in the country can seek access to GLP-1s or hormone therapy on demand, alongside the guidance they need to manage these therapies with a nuanced understanding of their own bodies and objectives.”
Shifting away from fragmented services
Maven’s philosophy is that women’s hormonal, metabolic, reproductive, mental, and physical health are deeply connected, and that care should follow a woman over time rather than treating each appointment as a first visit.
The platform includes GLP-1 care for women, which offers clinical weight management and metabolic care “built around more than a prescription.”
The program includes ongoing clinical oversight, medication management, hormone support, nutrition support, and strength guidance.The program includes ongoing clinical oversight, medication management, hormone support, nutrition support, and strength guidance. Treatment plans are informed by reproductive history, hormones, and life stage.
For hormone care for perimenopause and menopause, Maven looks at the “full picture, not just isolated symptoms.” Programs include consultations, personalized treatment plans, prescriptions when appropriate, and ongoing support as women’s bodies change over time.
Closing gaps in women’s care
The platform addresses a persistent challenge in women’s care, which is the gap between a prescription and the ongoing support these therapies require. Illustrating this need, Maven’s new report, “Beyond the Script: The Gap in Women’s Metabolic and Hormonal Care,” surveyed 1,538 women aged 30–60 and 520 health care providers across the US.
“When the system falls short, women are left connecting the dots for themselves: nearly half of women surveyed said they have turned to social media for health guidance,” details Maven.
Meanwhile, 37% of women who used GLP-1 or other medications for weight, metabolism, or hormones said the care felt limited, inconsistent, or lacked meaningful follow-up. And 47% believe having one provider who understands their whole health would most improve their care.
The report highlights that only 19% of women said their hormones are always taken into consideration in care related to their reproductive life stage. Around half (54%) suspected their symptoms were connected, but were treated as separate problems.
Patient care providers are also challenged, with 41% indicating they don’t have enough time to adequately support patients after prescribing GLP-1s. Notably, 73% of providers often see patients with symptoms spanning hormonal, metabolic, and mental health — yet fewer than half say their training left them fully equipped to treat them together.
Nearly half of women (46%) surveyed have tried a health product based on non-clinical recommendations.
Integrating clinician guidance
Advances in GLP-1s and hormone therapy have transformed what’s possible for women managing reproductive health, perimenopause, and menopause. However, recent Mayo Clinic research has found that women tend to avoid seeking care for symptoms around these areas.
Maven notes that the boom in these categories has produced platforms optimized for prescribing at scale — but women’s hormonal and metabolic health has become consumerized faster than it has become clinically integrated.
“The result is a system that moves fast and leaves women behind,” it stresses.
Dr. Janelle Duah, Maven Clinic’s associate medical director, comments: “What women are experiencing is not a series of isolated issues. .Hormonal and metabolic health impacts sleep, cardiovascular health, mental health, reproductive health, and overall quality of life.”
“Maven finally gives clinicians the ability to care for women in a way that reflects how women’s bodies actually work.”












